<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04825145</url>
  </required_header>
  <id_info>
    <org_study_id>s-20190142</org_study_id>
    <nct_id>NCT04825145</nct_id>
  </id_info>
  <brief_title>Preeclampsia and Contact Activation</brief_title>
  <official_title>Preeclampsia and Contact Activation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Region of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>OPEN</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lida og Oskar Nielsens Fond</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Esbjerg Fonden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gangsted Fonden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preeclampsia (PE) affects approximately 5% of all pregnancies with 2,500 cases registered&#xD;
      annually in Denmark. PE is characterized by incomplete modelling of the spiral arteries of&#xD;
      the uterus, hypertension, inflammation, hypercoagulability and proteinuria. Neonatal&#xD;
      complications and increased cardiovascular risk are common features of the syndrome.&#xD;
&#xD;
      PE shares pathophysiologic features with recognized protein misfolding disorders and&#xD;
      misfolded proteins are present in urine from women with PE. Misfolded proteins are potent&#xD;
      activators of the contact system (CAS) which is involved in inflammation, coagulation and&#xD;
      fibrinolysis.&#xD;
&#xD;
      Plasminogen activator inhibitor 2 (PAI-2) regulates important fibrinolytic processes in the&#xD;
      placenta. The oxidative milieu characterizing PE may trigger misfolding of PAI-2 which then&#xD;
      loose inhibitory capacity, but gain CAS-activating capacity. Thus, misfolding of PAI-2 may&#xD;
      affect the fibrinolytic system in the placenta and compromise the modelling of the spiral&#xD;
      arteries. Moreover, misfolded PAI-2 may contribute to the hypercoagulability and the&#xD;
      inflammatory conditions characterizing women with PE.&#xD;
&#xD;
      The aim of the present study is i) to characterize CAS in women with PE, ii) to study the&#xD;
      CAS-activating capacity of misfolded PAI-2 and iii) to develop and apply immunochemical&#xD;
      methods for determination of native and misfolded PAI-2 in plasma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 20, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The Contact Activation System (CAS)</measure>
    <time_frame>3 years</time_frame>
    <description>Biomarkers for the CAS in plasma Coagulation factor XII antigen/activity, High molecular weight kininogen (HK), Truncated (HK), Prekallikrein antigen, kallikrein generation, C1-esterase inhibitor, alpha-2-macroglobulin, Fast form alpha-2-macroglobulin, Thrombin generation,</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Misfolded Plasminogen activator inhibitor 2 (PAI-2)</measure>
    <time_frame>3 years</time_frame>
    <description>Biomarkers for misfolded PAI-2 in plasma Native PAI-2 antigen, Misfolded PAI-2, Native PAI-1 antigen,</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">226</enrollment>
  <condition>Preeclampsia</condition>
  <condition>CAS</condition>
  <condition>Misfolding Disease, Protein</condition>
  <arm_group>
    <arm_group_label>Preeclamptic women</arm_group_label>
    <description>Pregnant women who is diagnosed with preeclampsia during anytime of pregnancy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy pregnant women</arm_group_label>
    <description>Pregnant women without preeclampsia. Will be matched for body mass index, gestational age and age.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pregnancy</intervention_name>
    <description>Pregnancies complicated by preeclampsia</description>
    <arm_group_label>Preeclamptic women</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Preeclamptic women anytime of pregnancy compared to healthy pregnant women (control) at the&#xD;
        same gestational age, with matching BMI and age.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnant women developing preeclampsia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Healthy pregnant women&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>JÃ¸rgen B Gram, Professor</last_name>
    <role>Study Director</role>
    <affiliation>University of Southern Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne Cathrine M Godtfredsen</last_name>
    <phone>+4526887925</phone>
    <email>anne.cathrine.meldgaard.godtfredsen@rsyd.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gram, Professor</last_name>
    <phone>+4579182000</phone>
    <email>joergen.brodersen.gram@rsyd.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Unit for Thrombosis Research, University of Southern Denmark</name>
      <address>
        <city>Esbjerg</city>
        <zip>6700</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Cathrine M Godtfredsen, MD</last_name>
      <phone>+45 26887925</phone>
      <email>anne.cathrine.meldgaard.godtfredsen@rsyd.dk</email>
    </contact>
    <contact_backup>
      <last_name>Gram, Professor</last_name>
      <phone>+ 45 79182000</phone>
      <email>joergen.brodersen.gram@rsyd.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 25, 2021</study_first_submitted>
  <study_first_submitted_qc>March 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>March 30, 2021</last_update_submitted>
  <last_update_submitted_qc>March 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern Denmark</investigator_affiliation>
    <investigator_full_name>Anne Cathrine Meldgaard Godtfredsen</investigator_full_name>
    <investigator_title>Principal investigator, medical doctor, phd student</investigator_title>
  </responsible_party>
  <keyword>Contact activation system, PAI-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>Proteostasis Deficiencies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 1, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/45/NCT04825145/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

